I – Pharmaceutical Chemistry I:
Motivation of the research conducted, Vision and Aim:
Our group is mainly concerned with chemistry-driven approach and drug discovery capabilities to create small molecule drugs for the treatment of various pathological conditions. We aim at discovering novel molecules that are more potent, safer and with fewer side effects than those we already have.
Group research activities, expertise and focus points:
Enzyme Inhibitors:
-
Inhibitors for Hydrolase Enzymes, particularly Phosphodiesterases III, V, IX, X
-
Inhibitors of Tyrosine Kinase Enzymes e.g. EGFR, VEGF
-
Inhibitors of Serine/Threonine Kinase Enzyme, CDK1, CDK2, CDK5, PI3, PKCzeta
-
Inhibitors of Cytochrome P-450 Enzymes, CYP11B1, CYP11B2, CYP17, CYP19 (aromatase)
-
Kinesin EG5 Inhibitors
Hepatitis C- novel strategies for diagnosis and therapies:
-
Inhibitors to Hepatitis C Virus NS5A, NS3/4
Protein-Protein Interaction Inhibitors:
-
Inhibitors of Murine Double Minute 2
Ligands for G-Protein Coupled Receptors:
-
Ligands for Dopamine Receptors D1-D5
-
Ligands for Cannabinnoid Receptors (CB1-CB2)
Multi-component reactions
Computer Aided Drug Design:
-
Structure-Based Drug Discovery
-
Ligand based Drug Discovery, CoMFA/CoMSIA
-
Mining of Chemical Databases
Personalized Medicines:
-
Narrow and Broad Spectrum Anticancer Drugs
-
Development of New Methods for the Analysis of Pharmaceutical in Dosage Forms and Crude Forms
II – Pharmaceutical Chemistry II:
Motivation, Vision and Aim:
Research interests in Zlotos group are currently split into four areas of medicinal chemistry. One is the development of subtype-selective ligands for melatonin MT1 and MT2 receptors, the second is concerned with the development of allosteric modulators of muscarinic acetylcholine receptors, the third deals with ligands for the neuronal acetylcholine and glycine receptors, and the last one is the development of novel blockers of viral p7 channels. In each case, our role is that of synthetic medicinal chemists designing and preparing compounds mostly derived from natural products such as melatonin, strychnine and toxiferine I, as pharmacological tools specifically acting at receptors and ion channels mentioned above. Current research is strongly focused on the development of subtype selective melatonin receptor ligands targeting dimeric receptors.